Hong Kong Water Utilities Stock News

CK Hutchison Holdings (SEHK:1) is back in focus after intensifying its legal fight with Panama over the seizure of two Panama Canal ports, pursuing about US$2b in damages through international arbitration. See our latest analysis for CK Hutchison Holdings. At a share price of HK$61.55, CK Hutchison has a 90 day share price return of 11.71% and a year to date share price return of 13.98%. Its 1 year total shareholder return of 30.45% and 3 year total shareholder return of 53.26% point to...

Why JD Logistics’ latest earnings matter for shareholders JD Logistics (SEHK:2618) released fourth quarter and full year 2025 results, giving investors fresh detail on revenue, profit, and how its expanding logistics footprint and on demand delivery integration are feeding into the business. See our latest analysis for JD Logistics. The latest earnings release appears to have shifted sentiment quickly, with a 1 day share price return of 22.98% and a 7 day share price return of 13.07%...

WEILONG Delicious Global Holdings (SEHK:9985) has called a board meeting for 26 March 2026 to approve its 2025 annual results and consider a potential dividend, putting earnings quality and shareholder returns in sharper focus for investors. See our latest analysis for WEILONG Delicious Global Holdings. At a share price of HK$11.45, WEILONG Delicious Global Holdings has seen a 1 day share price return of 3.62%, while its 30 day share price return of 8.03% contrasts with a 1 year total...

If you are wondering whether InSilico Medicine Cayman TopCo is attractively priced or starting to look stretched, you are in the right place for a clear valuation breakdown. The share price closed at HK$55.5, with a 7 day return of 10.4% decline, a 30 day return of 10.7% decline, and a year to date return of 47.7%, which may signal changing views on its potential and risk. Recent attention on InSilico Medicine Cayman TopCo has been shaped by company specific news in the pharmaceuticals and...

CSPC Pharmaceutical Group (SEHK:1093) just received U.S. FDA clearance to start clinical trials for SYH2059, an inhaled PDE4B inhibitor for pulmonary fibrosis, highlighting its respiratory pipeline on an international stage. See our latest analysis for CSPC Pharmaceutical Group. That FDA green light comes after a series of fresh trial approvals in China for hemophilia and asthma treatments. It also arrives as CSPC Pharmaceutical Group’s 90 day share price return of 25.10% and 1 year total...

Why Morgan Stanley Is Flagging China Tower Now Morgan Stanley’s latest Asia Pacific report singles out China Tower (SEHK:788) as a defensive Hong Kong stock, highlighting its high dividends and relatively low share price volatility during a period of geopolitical tension in the region. See our latest analysis for China Tower. At a last close of HK$11.06, China Tower’s recent share price return has been mixed, with a 1 day gain of 0.73% and a 30 day share price return of 1.94%, but a 90 day...

Mobvista (SEHK:1860) has drawn fresh attention after issuing 2025 earnings guidance that points to higher revenue and a sharp profit increase, largely tied to its Mintegral advertising platform and improved operating efficiency. See our latest analysis for Mobvista. The guidance has arrived at a time when Mobvista’s recent momentum has been mixed, with a 2.33% 1 day share price return and 6.89% 7 day share price return contrasting with weaker 90 day and year to date share price returns. At...

Why China Telecom’s GLOMO wins are back on investors’ radar Fresh recognition for China Telecom (SEHK:728) at the 2026 Mobile World Congress, including multiple Global Mobile Awards tied to satellite connectivity and digital education, has put the stock back in focus for many investors. See our latest analysis for China Telecom. The recent GLOMO awards arrive as China Telecom’s share price trades at HK$5.1, with short term share price returns in positive territory but a 90 day share price...

Phase 2 UBT251 data puts obesity pipeline in focus United Laboratories International Holdings (SEHK:3933) has drawn fresh attention after its subsidiary completed a Chinese phase 2 trial of UBT251, a GLP-1, GIP and glucagon triple agonist for overweight and obesity. See our latest analysis for United Laboratories International Holdings. The phase 2 obesity data lands at a time when the share price has a 1 month share price return of 11.39% and a year to date share price return of 12.53%,...

Why Pacific Basin Shipping’s Latest Earnings Matter for Investors Pacific Basin Shipping (SEHK:2343) has just reported its full year 2025 results, with sales of US$2,081.04 million and net income of US$58.17 million, alongside commentary on shareholder returns and capital allocation. The company also pointed to a 46% total shareholder return, a new US$250 million sustainability linked facility, and an ongoing share buyback. Together, these factors frame how management is currently thinking...

In February 2026, Earendil Labs announced a collaboration with WuXi XDC Cayman Inc., securing an exclusive global license to WuXi XDC’s proprietary WuXiTecan-2 payload-linker platform for multiple targets, alongside up to approximately US$885 million in potential upfront and milestone payments plus tiered royalties. The partnership combines Earendil’s AI-driven antibody discovery with WuXi XDC’s integrated bioconjugate CRDMO capabilities, positioning WuXi XDC as a key enabler in...

Semiconductor Manufacturing International (SEHK:981) is now accessible to Thai investors via newly listed depositary receipts on the Stock Exchange of Thailand. The DRs give investors in Thailand indirect exposure to SMIC shares that trade in Hong Kong at around HK$61.8. This cross border listing move broadens access to SMIC equity and may affect trading activity in its Hong Kong listed shares over time. For you as an investor, the new Thai DRs open another route into Semiconductor...

Shanghai Chicmax Cosmetic (SEHK:2145) issued unaudited guidance for 2025, projecting revenue of RMB 9,100.0 million to RMB 9,200.0 million and profit of RMB 1,140.0 million to RMB 1,160.0 million, highlighting momentum across its key brands. See our latest analysis for Shanghai Chicmax Cosmetic. The upbeat 2025 guidance sits against a mixed share price backdrop, with a 7% 1 day share price return and a 1 year total shareholder return of 68.27%. At the same time, the 90 day share price return...

JD Health’s latest earnings and why they matter JD Health International (SEHK:6618) has just reported its full year 2025 results, with sales of CNY 73,441.49 million and net income of CNY 5,375.41 million, catching investor attention. See our latest analysis for JD Health International. JD Health International’s full year earnings arrive at a time when the 1-year total shareholder return of 35.38% contrasts with a 20.20% 30-day share price decline and a 19.60% 90-day share price decline,...

CK Asset Holdings (SEHK:1113) has set a date for its next key catalyst, with the board scheduled to meet in Hong Kong on 19 March 2026 to approve the 2025 annual results and consider a final dividend. See our latest analysis for CK Asset Holdings. At a share price of HK$47.9, CK Asset Holdings has seen a 30 day share price return of 4.27% and a 90 day share price return of 17.40%, with a 1 year total shareholder return of 42.02%. This performance may lead some investors to reassess the stock...

Dividend announcements put Shangri-La Asia in focus Shangri-La Asia (SEHK:69) has drawn investor attention after announcing a final single tier dividend of HK$0.06 per share for FY2025, together with a proposed THB0.50 per share payout pending shareholder approval. The Hong Kong dollar dividend is scheduled for payment on June 29, 2026, with an ex dividend date of June 9 and an entitlement date of June 10, while the Thai baht proposal totals THB65 million. See our latest analysis for...

How Prada (SEHK:1913) Just Performed Prada (SEHK:1913) has released its FY 2025 numbers with first half revenue at €2.7 billion and basic EPS of €0.15, setting the tone for how the rest of the year may shape up for the luxury group. The company has seen revenue move from €2.5 billion and EPS of €0.15 in 1H 2024 to €2.7 billion and EPS of €0.18 in 2H 2024, finishing the trailing twelve months with €5.7 billion of revenue and EPS of €0.33. With a trailing net profit margin of 14.9% and growth...

Allied Group (SEHK:373) is in focus after the board announced that long serving executive director Mr. Edwin Lo King Yau will retire. Director of investment Mr. Mark Wong Tai Chun will assume board and representative roles. See our latest analysis for Allied Group. The leadership reshuffle comes after a strong run in the shares, with Allied Group’s 30 day share price return of 16.26% and 90 day share price return of 50.67%, while its 1 year total shareholder return of 131.72% suggests recent...

What Pop Mart’s recent share performance tells you With no single headline event driving attention to Pop Mart International Group (SEHK:9992) right now, recent price moves and financial figures offer a useful snapshot of how the market is treating the stock. See our latest analysis for Pop Mart International Group. At the latest share price of HK$207.4, the stock’s short term momentum looks softer, with a 7 day share price return of 9.75% and 30 day share price return of 12.56%, while the 1...

Government capital plan puts ICBC back in focus Industrial and Commercial Bank of China (SEHK:1398) has moved back into the spotlight after Beijing outlined a planned ¥300b capital injection into state owned banks through special treasury bonds and broader financial sector reforms. With investors watching how support may be allocated across the system, attention is turning to what this could mean for ICBC’s capital position, risk bearing capacity, and the way it manages exposure to property...

SINOPEC Engineering (Group) has announced that its board will meet on 13 March 2026 to review and approve the company’s 2025 annual results and consider a dividend distribution plan, which will later be submitted to shareholders at the annual general meeting. This upcoming board decision is important because it will pair fresh financial disclosures with a potential dividend proposal, giving investors clearer information on how the board is balancing capital returns and future investment...

If you are trying to figure out whether BYD’s current share price makes sense, you are in the right place. This article focuses on what the numbers say about value rather than the hype around electric vehicles. BYD last closed at HK$94.70, with returns of 5.2% over 30 days, a 19.1% decline over 1 year and gains of 45.6% over 3 years and 53.5% over 5 years. This gives a mixed picture of recent price momentum and changing risk sentiment. Recent coverage around BYD has focused on its position...

China has imposed an urgent ban on diesel and gasoline exports by state oil giants, including China Petroleum & Chemical (Sinopec), in response to escalating geopolitical tensions involving the US, Israel, and Iran. The suspension affects shipments to regional buyers and could tighten fuel supplies across the Asia Pacific market. The move marks a major shift in operating flexibility for SEHK:386, which has been a key supplier of refined products to neighboring economies. For China Petroleum...

XtalPi Holdings (SEHK:2228) has outlined a plan to reach profitability in 2025. Management links the shift to tripled revenue and improved performance in core businesses. A multi billion dollar collaboration with DoveTree is cited as a key factor in the updated outlook. The company highlights gains from recent partnerships as part of its 2025 profitability plan. XtalPi Holdings operates at the intersection of technology and biopharma, focusing on drug discovery and related services. For...